: Ongoing antitrust scrutiny of pharmacy benefit managers (PBMs) and potential changes to Medicare Advantage rates remain key risks for the 2027 fiscal year.
: The stock trades at roughly 11x forward earnings , significantly below its historical average of 12-15x. Morningstar estimates a fair value of $97.00 . should i buy cvs stock
: CVS offers a 3.4% dividend yield , which is more than double the S&P 500 average. : Ongoing antitrust scrutiny of pharmacy benefit managers
Some analysts project a 12-month price target averaging , implying over 20% upside. implying over 20% upside.